Obinutuzumab Injection [Gazyva]

Preclinical

VVitebsk Regional Clinical Cancer Centre

Obinutuzumab Injection [Gazyva] is one of 5 therapeutic programs targeting Chronic Lymphocytic Leukaemia (CLL). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Chronic Lymphocytic Leukaemia (CLL)Recruiting

Chronic Lymphocytic Leukaemia (CLL)Preclinical

Recruiting

Competition

Competitive Landscape

4 competitors in Chronic Lymphocytic Leukaemia (CLL)

#DrugCompanyPhaseTrials

Gazyva

Roche

Phase 3

1 2

Venclexta

AbbVie

Phase 3

1 3

Imbruvica

PPharmacyclics LLC.

Phase 3

1 4

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

3 5

Obinutuzumab Injection [Gazyva]

VVitebsk Regional Clinical Cancer Centre

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukaemia (CLL)1 trial

Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.

Recruiting·VVitebsk Regional Clinical Cancer Centre·Preclinical·NCT06762431·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Obinutuzumab Injection [Gazyva]. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Obinutuzumab Injection [Gazyva]. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Vitebsk Regional Clinical Cancer Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: VVitebsk Regional Clinical Cancer Centre

Obinutuzumab Injection [Gazyva]

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Chronic Lymphocytic Leukaemia (CLL)1 trial

References

Drug Info

Quick Facts

Related News